Urogen
Princeton, US · 3 known investors
UroGen is a biopharmaceutical company developing and commercializing treatments for urological cancers, including FDA-approved therapies such as JELMYTO and ZUSDURI built on its RTGel technology. Its pipeline focuses on uro-oncology indications like non-muscle invasive bladder cancer.
Founders & leadership
EB
Elizabeth BarrettExecutive
MS
Mark Schoenberg, M.D.Executive
JS
Jason SmithNamed on SEC filing
AB
Arie Belldegrun, M.D.Named on SEC filing
DW
Dan WildmanNamed on SEC filing
DK
Don KimNamed on SEC filing
JA
James A. Robinson, Jr.Named on SEC filing
Board
FC
Fred Cohen, M.D.Board director
RN
Ran NussbaumBoard director
SH
Stuart Holden, M.D.Board director
CB
Cynthia ButittaBoard director
LW
Leana Wen, M.D., MScBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$120M disclosed across 1 round · 2023
▶$120MraisedAug 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$120MraisedAug 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stuart Holden, M.D.Director
- Jason SmithExecutive Officer
- Arie Belldegrun, M.D.Director
- Dan WildmanDirector
- Fred Cohen, M.D.Director
- Don KimExecutive Officer
- James A. Robinson, Jr.Director
- Cynthia ButittaDirector
- Ran NussbaumDirector
- Elizabeth BarrettExecutive Officer, Director
- Leana Wen, M.D., MScDirector
- Mark Schoenberg, M.D.Executive Officer
- Offering amount
- $120M
- Amount sold
- $120M
- Sales commissions
- $3.2M
- Placement agents
- H.C. Wainwright & Co., LLC, BofA Securities, Inc.
- First sale
- Jul 2023
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Urogen do?
- UroGen is a biopharmaceutical company developing and commercializing treatments for urological cancers, including FDA-approved therapies such as JELMYTO and ZUSDURI built on its RTGel technology. Its pipeline focuses on uro-oncology indications like non-muscle invasive bladder cancer.
- Who are Urogen's investors?
- Urogen's investors include Aisling Capital, Monograph Capital Partners, Pontifax Venture Capital.
- How much funding has Urogen raised?
- Urogen has disclosed $120M raised across 1 round.
- Where is Urogen headquartered?
- Urogen is headquartered in Princeton, US.